Milestone Fee. Upon the issuance of a Reissue Patent, Licensee shall pay to Licensor a Milestone Fee in the amount of [*** Redacted]. Such Milestone Fee shall be payable within thirty(30) days of Licensee's written notification to Licensee of such Reissue Patent. Prior to May 29, 2003, if Licensee notifies Licensor that it does not wish to cause Licensor to seek a Reissue Patent, then such notification shall trigger the milestone fee, requiring Licensee to pay to Licensor the Milestone Fee. In addition, [*** Redacted] of such Milestone Fee shall be payable to Licensor (if not previously paid) in the event that the Contingent Option is exercised pursuant to Section 3.6(d) of this Agreement, and any such payment shall reduce any Milestone Fee payable to Licensor under the preceding sentence of this Section 4.0; provided, however, in no event shall Licensee make any such payment to Licensor if the *** Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. Licensee has previously paid Licensor the Milestone Fee in full asset forth in said preceding sentence.
Milestone Fee. Within:
(a) 30 days after the achievement of a Clinical and Regulatory Milestone; and
(b) 30 days after the achievement of a Commercial Milestone, Cortendo must pay to ATL the applicable Milestone Fee.
Milestone Fee. 5.1.1 In consideration of the licence granted to Kolltan pursuant to Clause 4 above, upon the one year anniversary of the first Regulatory Approval for each Product under this License Agreement that is manufactured by Lonza, Kolltan shall pay Lonza a one-time milestone fee of £[**] pounds) in respect of such Product.
Milestone Fee. Genzyme shall pay Alnylam Fifty Million Dollars ($50,000,000) upon the dosing of the first patient in the first Phase III Study for a Global AT3 Licensed Product.
Milestone Fee. The Milestone Fee is only applicable to a Transaction (as defined in Section 1 above). A $15,000 non-refundable, non-contingent milestone fee (the “MilestoneFee”) due within three (3) days of full execution of a Transaction/Service Contract for eachcontemplated Transaction. For purposes of this Milestone Fee and the Consulting Fee, and by way of example, each license (i) purchased, (ii) sold, and/or (ii) funded constitutes an individual Transaction. As an example, if a Licensee sells three dispensary licenses, You would owe to CannaMatch a total of $45,000 ($15,000 x 3). The Milestone Fee will be credited against the Consulting Services Fee, if and when paid by You. You agree, however, that the Milestone Fee is notcontingent upon closing a Transaction.
Milestone Fee. Notwithstanding any provisions of the Credit Agreement and the other Loan Documents to the contrary, if the Commitments have not been terminated and the Obligations have not been paid in full in immediately available funds to Lender on or before March 31, 2017, Borrowers shall pay to Lender a fee in the amount of $75,000 (the “Milestone Fee”), which Milestone Fee shall be retained by Lender (solely for its account) and shall be fully earned on the date hereof and non-refundable when paid.
Milestone Fee. BIG shall pay STELLAR a milestone fee in the amount of two hundred and fifty thousand US Dollar (250,000 US $) payable within one (1) month upon confirmation by BIG or BIG Affiliates of (the following conditions hereinafter together the “Milestone”):
1. the feasibility of increasing the KLHsu yield (starting from a 5 gram quantity of ASP KLH starting material) to a yield of approximately 60% (but not less than a 50% yield) KLHsu.
2. with a method that is supported by appropriate Standard Operating Procedure (SOP´s) for method qualification and validation in accordance with regulatory requirements, and
3. yielding to KLHsu proteins that are suitable for the NHL-Vaccines. For the avoidance of doubt BIG does not have to pay STELLAR this fee if the Milestone is not achieved within the duration of this Agreement pursuant to paragraph 9.1.
Milestone Fee. Assignee shall pay Xxxxxx Estate a fee equal to two hundred thousand Dollars ($200,000) as a milestone payment within thirty (30) days after the end of the calendar month in which the first human subject is first dosed with a Product in the first human clinical trial sponsored by or on behalf of Assignee, its Affiliate or a Licensee. Such milestone payment shall be payable a maximum of one (1) time only under this Agreement, even if multiple clinical trials of Product are conducted under this Agreement.
Milestone Fee. A fee of $50,000 shall be due and payable on November 30, 2016, if Borrower’s Recurring Revenue, measured as of October 31, 2016 and annualized for the preceding 6 months, is not greater than $15,000,000.
Milestone Fee. Upon the first approval of an NDA with respect to a GDNF Product achieved by AMT and/or its Affiliates (the “Approval Milestone”), AMT shall promptly (and, in any event, no later than [**] days) notify Amgen in writing of such occurrence and the amount received, and Amgen will invoice AMT for a one-time payment in the amount of the greater of (a) ten million US Dollars (US$10,000,000) and (b) [**]% of any milestone payments received by AMT from Third Parties in respect of the Approval Milestone. Such payment shall be due and payable by AMT within [**] days after receipt of the invoice from Amgen. The milestone fee is payable only once and shall not be payable for subsequent or repeated achievements of such milestone event with one or more of the same or different GDNF Products.
